Arts

Arts Therapeutics is a French biotechnology company focused on developing a new class of pro-apoptotic drugs for the treatment of cancer. The company's technology is based on the discovery of the ARTS protein (a pro-apoptotic septin-4 isoform), which acts as a natural antagonist of IAPs (Inhibitor of Apoptosis Proteins), particularly XIAP. By mimicking the function of ARTS, the company aims to overcome resistance to apoptosis in cancer cells, providing a novel mechanism to trigger programmed cell death in various malignancies. Their lead programs are currently in the pre-clinical stage, targeting both hematological and solid tumors.